131 related articles for article (PubMed ID: 16054931)
1. Effect of rimonabant on weight reduction and cardiovascular risk.
Esposito K; Giugliano D
Lancet; 2005 Jul 30-Aug 5; 366(9483):367-8; author reply 369-70. PubMed ID: 16054931
[No Abstract] [Full Text] [Related]
2. Effect of rimonabant on weight reduction and cardiovascular risk.
Astrup A
Lancet; 2005 Jul 30-Aug 5; 366(9483):368; author reply 369-70. PubMed ID: 16054932
[No Abstract] [Full Text] [Related]
3. [The endocannabinoid system, overweight, and the CB1-endocannabinoid-receptor antagonist rimonabant].
Boekholdt SM; Jukema JW; Peters RJ
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2615-9. PubMed ID: 18161262
[TBL] [Abstract][Full Text] [Related]
4. Effect of rimonabant on weight reduction and cardiovascular risk.
van Oosten B; Killestein J; Polman Ch
Lancet; 2005 Jul 30-Aug 5; 366(9483):368-9; author reply 369-70. PubMed ID: 16054933
[No Abstract] [Full Text] [Related]
5. Rimonabant in obese patients with type 2 diabetes.
Randall MD; Kendall DA; Bennett AJ; O'Sullivan SE
Lancet; 2007 Feb; 369(9561):555. PubMed ID: 17307094
[No Abstract] [Full Text] [Related]
6. [New drugs; rimonabant].
van Bronswijk H; Dubois EA; Pijl H; Cohen AF
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2620-2. PubMed ID: 18161263
[TBL] [Abstract][Full Text] [Related]
7. Effect of rimonabant on weight reduction and cardiovascular risk.
Hirschel B
Lancet; 2005 Jul 30-Aug 5; 366(9483):369; author reply 369-70. PubMed ID: 16054934
[No Abstract] [Full Text] [Related]
8. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia.
Després JP; Golay A; Sjöström L;
N Engl J Med; 2005 Nov; 353(20):2121-34. PubMed ID: 16291982
[TBL] [Abstract][Full Text] [Related]
9. New diet drug stirs high hopes. But can the pill, rimonabant, liver up to large expectations?
Heart Advis; 2005 Feb; 8(2):3. PubMed ID: 15806687
[No Abstract] [Full Text] [Related]
10. CB(1) blockade-induced weight loss over 48 weeks decreases liver fat in proportion to weight loss in humans.
Bergholm R; Sevastianova K; Santos A; Kotronen A; Urjansson M; Hakkarainen A; Lundbom J; Tiikkainen M; Rissanen A; Lundbom N; Yki-Järvinen H
Int J Obes (Lond); 2013 May; 37(5):699-703. PubMed ID: 22828945
[TBL] [Abstract][Full Text] [Related]
11. Rimonabant: obituary for a wonder drug.
Boekholdt SM; Peters RJ
Lancet; 2010 Aug; 376(9740):489-90. PubMed ID: 20709215
[No Abstract] [Full Text] [Related]
12. [Selective cannabinoid receptor antagonists].
Kreutz S; Korf HW; Schubert-Zsilavecz M
Pharm Unserer Zeit; 2006; 35(6):512-20. PubMed ID: 17137082
[No Abstract] [Full Text] [Related]
13. The cardiometabolic drug rimonabant: after 2 years of RIO-Europe and STRADIVARIUS.
Kintscher U
Eur Heart J; 2008 Jul; 29(14):1709-10. PubMed ID: 18556715
[No Abstract] [Full Text] [Related]
14. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study.
Van Gaal LF; Rissanen AM; Scheen AJ; Ziegler O; Rössner S;
Lancet; 2005 Apr 16-22; 365(9468):1389-97. PubMed ID: 15836887
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for obesity--promise and uncertainty.
Yanovski SZ
N Engl J Med; 2005 Nov; 353(20):2187-9. PubMed ID: 16291989
[No Abstract] [Full Text] [Related]
16. Rimonabant in obese patients with type 2 diabetes.
Shapiro H; Singer P
Lancet; 2007 Feb; 369(9561):553-4; author reply 554-5. PubMed ID: 17307091
[No Abstract] [Full Text] [Related]
17. Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction.
Gadde KM
Curr Drug Targets Cardiovasc Haematol Disord; 2005 Dec; 5(6):549-56. PubMed ID: 16503875
[TBL] [Abstract][Full Text] [Related]
18. [Positive influence on cardiovascular risk factor by blocking the endocannabinoid system].
Chatterjee T; Ritz A; Ince H; Nienaber ChA; Rehders TC
Praxis (Bern 1994); 2008 May; 97(11):613-21. PubMed ID: 18592956
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program.
Van Gaal L; Pi-Sunyer X; Després JP; McCarthy C; Scheen A
Diabetes Care; 2008 Feb; 31 Suppl 2():S229-40. PubMed ID: 18227491
[TBL] [Abstract][Full Text] [Related]
20. Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors.
Tonstad S
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):156-62. PubMed ID: 16487916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
